Skip to main content
. 2019 Oct 1;8(10):1186. doi: 10.3390/cells8101186

Figure 5.

Figure 5

Hematoxilin and eosin (H&E, 5×, 10× and 20× magnification) of HGSOC sections collected at D-LPS (pre-NACT) and at IDS (post-NACT) and immunohistochemical staining for p53 (10×, 20× and 40× magnification). (a–c) H&E of bouin-fixed, paraffin-embedded tumor tissue collected at D-LPS showing the serous ovarian carcinoma architecture of HGSOC case with somatic mutation in TP53 (a: 5×; b: 10×; c: 20×); (d–f) Absent (-) nuclear p53 expression on tumor tissue collected at D-LPS of HGSOC case with somatic mutation in TP53 (d: 10×; e: 20×; f: 40×); (g–i) H&E of formalin-fixed, paraffin-embedded tumor tissue collected at IDS showing the serous ovarian carcinoma architecture of HGSOC case with somatic mutation in TP53 (g: 5×; h: 10×; i: 20×); (l–n) Absent (-) nuclear p53 expression on tumor tissue collected at IDS of HGSOC case with somatic mutation in TP53 (l: 10×; m: 20×; n: 40×). No cytoplasmic staining was observed. NACT: neo-adjuvant chemotherapy; HGSOC: high-grade serous ovarian cancer; D-LPS: diagnostic laparoscopy; IDS: interval debulking surgery.